Literature DB >> 32341520

Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging.

Liam A McDonnell1,2, Judith V M G Bovée3, Bram Heijs4, Stephanie Holst-Bernal1, Marieke A de Graaff3, Inge H Briaire-de Bruijn3, Mar Rodriguez-Girondo5, Michiel A J van de Sande6, Manfred Wuhrer1.   

Abstract

Myxoid liposarcoma (MLS) is the second most common subtype of liposarcoma, accounting for ~6% of all sarcomas. MLS is characterized by a pathognomonic FUS-DDIT3, or rarely EWSR1-DDIT3, gene fusion. The presence of ≥5% hypercellular round cell areas is associated with a worse prognosis for the patient and is considered high grade. The prognostic significance of areas with moderately increased cellularity (intermediate) is currently unknown. Here we have applied matrix-assisted laser desorption/ionization mass spectrometry imaging to analyze the spatial distribution of N-linked glycans on an MLS microarray in order to identify molecular markers for tumor progression. Comparison of the N-glycan profiles revealed that increased relative abundances of high-mannose type glycans were associated with tumor progression. Concomitantly, an increase of the average number of mannoses on high-mannose glycans was observed. Although overall levels of complex-type glycans decreased, an increase of tri- and tetra-antennary N-glycans was observed with morphological tumor progression and increased tumor histological grade. The high abundance of tri-antennary N-glycan species was also associated with poor disease-specific survival. These findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32341520     DOI: 10.1038/s41374-020-0435-2

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  46 in total

1.  Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases.

Authors:  C R Antonescu; S J Tschernyavsky; R Decuseara; D H Leung; J M Woodruff; M F Brennan; J A Bridge; J R Neff; J R Goldblum; M Ladanyi
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

2.  Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.

Authors:  Marieke A de Graaff; Jamie S E Yu; Hannah C Beird; Davis R Ingram; Theresa Nguyen; Jeffrey Juehui Liu; Svetlana Bolshakov; Károly Szuhai; Pierre Åman; Keila E Torres; Dina Lev; Torsten O Nielsen; Judith V M G Bovée; Alexander J Lazar; Neeta Somaiah
Journal:  Lab Invest       Date:  2016-06-06       Impact factor: 5.662

3.  The expanded histologic spectrum of myxoid liposarcoma with an emphasis on newly described patterns: implications for diagnosis on small biopsy specimens.

Authors:  Karen J Fritchie; John R Goldblum; Raymond R Tubbs; Yang Sun; Paula Carver; Steven D Billings; Brian P Rubin
Journal:  Am J Clin Pathol       Date:  2012-02       Impact factor: 2.493

4.  Proteomic signatures corresponding to histological classification and grading of soft-tissue sarcomas.

Authors:  Yoshiyuki Suehara; Tadashi Kondo; Kiyonaga Fujii; Tadashi Hasegawa; Akira Kawai; Kunihiko Seki; Yasuo Beppu; Toshihide Nishimura; Hisashi Kurosawa; Setsuo Hirohashi
Journal:  Proteomics       Date:  2006-08       Impact factor: 3.984

5.  Prognostic factors for the recurrence of myxoid liposarcoma: 20 cases with up to 8 years follow-up.

Authors:  M Lemeur; J-C Mattei; P Souteyrand; C Chagnaud; G Curvale; A Rochwerger
Journal:  Orthop Traumatol Surg Res       Date:  2015-01-09       Impact factor: 2.256

6.  Clinicopathologic prognostic factors of pure myxoid liposarcoma of the extremities and trunk wall.

Authors:  Yoshihiro Nishida; Satoshi Tsukushi; Hiroatsu Nakashima; Naoki Ishiguro
Journal:  Clin Orthop Relat Res       Date:  2010-11       Impact factor: 4.176

7.  Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations.

Authors:  Aviad Hoffman; Markus P H Ghadimi; Elizabeth G Demicco; Chad J Creighton; Keila Torres; Chiara Colombo; Tingsheng Peng; Kristelle Lusby; Davis Ingram; Jason L Hornick; Wei-Lie Wang; Vinod Ravi; Alexander J Lazar; Dina Lev; Raphael E Pollock
Journal:  Cancer       Date:  2013-02-07       Impact factor: 6.860

8.  Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma.

Authors:  Elizabeth G Demicco; Keila E Torres; Markus P Ghadimi; Chiara Colombo; Svetlana Bolshakov; Aviad Hoffman; Tingsheng Peng; Judith V M G Bovée; Wei-Lien Wang; Dina Lev; Alexander J Lazar
Journal:  Mod Pathol       Date:  2011-10-21       Impact factor: 7.842

9.  Involvement of tumor suppressors PTEN and p53 in the formation of multiple subtypes of liposarcoma.

Authors:  A M Puzio-Kuter; S V Laddha; M Castillo-Martin; Y Sun; C Cordon-Cardo; C S Chan; A J Levine
Journal:  Cell Death Differ       Date:  2015-03-27       Impact factor: 15.828

10.  miR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma.

Authors:  Y Nezu; K Hagiwara; Y Yamamoto; T Fujiwara; K Matsuo; A Yoshida; A Kawai; T Saito; T Ochiya
Journal:  Oncogene       Date:  2016-05-09       Impact factor: 9.867

View more
  6 in total

Review 1.  Glycan Imaging Mass Spectrometry: Progress in Developing Clinical Diagnostic Assays for Tissues, Biofluids, and Cells.

Authors:  Calvin R K Blaschke; Colin T McDowell; Alyson P Black; Anand S Mehta; Peggi M Angel; Richard R Drake
Journal:  Clin Lab Med       Date:  2021-04-24       Impact factor: 2.172

Review 2.  Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging.

Authors:  Ruben D Houvast; Mireille Vankemmelbeke; Lindy G Durrant; Manfred Wuhrer; Victor M Baart; Peter J K Kuppen; Lioe-Fee de Geus-Oei; Alexander L Vahrmeijer; Cornelis F M Sier
Journal:  Cancers (Basel)       Date:  2020-12-21       Impact factor: 6.639

Review 3.  Proteomic and Metabolomic Profiling in Soft Tissue Sarcomas.

Authors:  Madhumeeta Chadha; Paul H Huang
Journal:  Curr Treat Options Oncol       Date:  2022-02-16

4.  Characterization of lipomatous tumors with high-resolution 1H MRS at 17.6T: Do benign lipomas, atypical lipomatous tumors and liposarcomas have a distinct metabolic signature?

Authors:  Santosh Kumar Bharti; Brett A Shannon; Raj Kumar Sharma; Adam S Levin; Carol D Morris; Zaver M Bhujwalla; Laura M Fayad
Journal:  Front Oncol       Date:  2022-09-09       Impact factor: 5.738

5.  MALDI-2 for the Enhanced Analysis of N-Linked Glycans by Mass Spectrometry Imaging.

Authors:  Bram Heijs; Alexander Potthoff; Jens Soltwisch; Klaus Dreisewerd
Journal:  Anal Chem       Date:  2020-10-07       Impact factor: 6.986

6.  High-Mannose N-Glycans as Malignant Progression Markers in Early-Stage Colorectal Cancer.

Authors:  Fanny Boyaval; Hans Dalebout; René Van Zeijl; Wenjun Wang; Arantza Fariña-Sarasqueta; Guinevere S M Lageveen-Kammeijer; Jurjen J Boonstra; Liam A McDonnell; Manfred Wuhrer; Hans Morreau; Bram Heijs
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.